Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leukotuximab
- Development stage
- Phase 1
- Lead developer
- Aprogen
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DNP001 (leukotuximab) is a chimeric monoclonal antibody targeting the JL1 epitope of sialophorin (CD43), a transmembrane glycoprotein highly expressed on the surface of acute leukemia cells but absent on mature peripheral blood cells and normal tissues. Originally developed by the University of Seoul and DiNonA, the asset was licensed to 3SBio for development in China and to Aprogen for subsequent development, with DiNonA later being acquired by Kumho HT. DNP001 exerts cytotoxic effects on JL1-positive leukemia cells, primarily through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It has been evaluated in Phase 1 clinical trials for the treatment of acute leukemia and myelodysplastic syndrome (MDS). Additionally, the platform is being explored for optimization as a CAR-T cell therapy or bispecific antibody for solid cancers, including gastric cancer.
- Other names
- Anti-JL1 monoclonal antibodyAnti-JL-1 monoclonal antibodyAnti-JL 1 monoclonal antibodyanti-JL1 antibodyanti-JL-1 antibodyanti-JL 1 antibody
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on leukotuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leukotuximab.